Objective: We aimed to demonstrate the real world differences in a single center.

Background: Number of deep brain stimulation (DBS) and levodopa-carbidopa continuous infusion gel (LCIG) therapies for Parkinson’s disease (PD) have been gradually increase in Japan. Differences in indication and outcome between these DATs should be investigate in hospitals available both both therapies, however, such comprehensive centers are still available at some facilitieslimited.

Method: We investigated PD patients undergoing DBS or LCIG in our hospital between April 2016 and March 2019. Selection of the DATs was in accordance with the Japanese Guidelines. Mental state, motor and non-motor symptoms and levodopa equivalent daily dose (LEDD) during the observation period were examined in all patients.

Results: We investigated 24 PD patients undergoing DBS (n=14, age 67.8±11.9 years, disease duration 10.2±3.8 years) or LCIG (n=10, age 66.0±7.4 years, disease duration 11.6±4.2 years). Mean observational period was 15±17 months in DBS group, and 10.9±8.2 months in LCIG group. During the observation period, there was no deterioration in Hoehn-Yahr severity score in both groups. Mean LEDD was increased in LCIG group (69.3 mg) and reduced in DBS group (142 mg). In DBS group, worsening of wearing-off phenomenon was observed in one patient, and worsening of dyskinesia was observed in one patient, but not in LCIG group. Re-hospitalization due to serious problem after DAT was observed in 4; 2 patients in DBS group and 2 patients in LCIG group, but DAT was continued in all patients.

Conclusion: Strict selection of different DATs by adhering the guidelines appeared to provide good long term effects on advanced PD.

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/indication-and-long-term-outcome-of-device-aided-therapies-in-advanced-parkinsons-disease/